Please ensure Javascript is enabled for purposes of website accessibility

Report: Trump Administration Picks 5 Coronavirus Vaccine Candidates to Support

By Keith Speights – Jun 3, 2020 at 5:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The White House reportedly plans to route extra federal funds and other assistance to the companies developing those potential SARS-CoV-2 vaccines.

The Trump administration has picked five COVID-19 vaccine candidates that it views as the most likely to be successful, according to an article published Wednesday by The New York Times. The newspaper stated that four of the companies whose candidates made the list are U.S.-based: Moderna (MRNA 0.15%), Johnson & Johnson (JNJ -0.71%), Merck (MRK -0.60%), and Pfizer (PFE -0.91%). The other is U.K.-headquartered AstraZeneca (AZN -0.13%), which is partnering with the University of Oxford. Pfizer is also partnering with Germany-based BioNTech (BNTX 0.96%). More than 100 organizations and companies are currently working on vaccines to prevent COVID-19.

Moving at "warp speed"

The selection of these finalists is part of the administration's Operation Warp Speed, an initiative to rapidly develop a vaccine for SARS-CoV-2, the coronavirus that causes COVID-19. President Trump announced this effort on May 15, referring to it as a "massive scientific, industrial, and logistical endeavor unlike anything our country has seen since the Manhattan Project."

Gloved hands holding coronavirus vaccine bottles

Image source: Getty Images.

Each of the drugmakers selected by the White House will receive access to extra federal funds to support their coronavirus vaccine development, as well as logistical support and assistance with clinical trials. Moderna, Johnson & Johnson, and the AstraZeneca-Oxford partnership have already received a combined $2.2 billion in federal funding.

The vaccines being developed by Moderna and the AstraZeneca-Oxford team are currently being evaluated in phase 2 clinical studies. Pfizer and BioNTech initiated a phase 1/2 study of their COVID-19 vaccine candidate in April. Johnson & Johnson and Merck haven't initiated clinical studies of their vaccine candidates yet.

These five finalists haven't been officially named by the White House yet. The New York Times stated that senior Trump administration officials indicated that an announcement will be made "in the next few weeks."

Keith Speights owns shares of Pfizer. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$86.12 (-0.60%) $0.52
Pfizer Inc. Stock Quote
Pfizer Inc.
$43.76 (-0.91%) $0.40
Johnson & Johnson Stock Quote
Johnson & Johnson
$163.36 (-0.71%) $-1.17
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$54.84 (-0.13%) $0.07
Moderna, Inc. Stock Quote
Moderna, Inc.
$118.25 (0.15%) $0.18
BioNTech SE Stock Quote
BioNTech SE
$134.88 (0.96%) $1.28

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.